MARKET

SONN

SONN

Sonnet Biotherapeutc Hldng Inc
NASDAQ
1.070
-0.015
-1.38%
Pre Market: 1.070 0 0.00% 08:30 02/06 EST
OPEN
1.110
PREV CLOSE
1.085
HIGH
1.110
LOW
1.040
VOLUME
7.77K
TURNOVER
--
52 WEEK HIGH
9.37
52 WEEK LOW
0.9120
MARKET CAP
8.49M
P/E (TTM)
-0.1565
1D
5D
1M
3M
1Y
5Y
Sonnet Biotherapeutics Completes Two Ind-enabling Toxicology Studies With Son-1210 In Non-human Primates, Son-1210 Elicited No Serious Adverse Events, Shares Jump
Benzinga · 5d ago
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 01/30 21:31
Why FARO Technologies Shares Are Trading Lower By 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga · 01/20 18:24
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 01/20 17:31
Nordstrom, Bed Bath & Beyond, Synlogic among premarket losers' pack
Seeking Alpha · 01/20 13:17
Why Netflix Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
Benzinga · 01/20 12:55
BRIEF-Sonnet Biotherapeutics Holdings Inc Files For Common Stock Offering - SEC Filing
Reuters · 01/19 22:33
Sonnet Bio Reveals Pharmacokinetic, Pharmacodynamic Data In Early-Stage SON-1010 Trial
Benzinga · 01/19 16:28
More
About SONN
Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company. The Company's technology, namely fully human albumin binding (FHAB), utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The Company designed the FHAB construct to improve drug accumulation in cancer tumors, well as to extend the duration of activity in the body. Its lead asset, SON-1010, is a fully human single-chain version of Interleukin 12 (IL-12), covalently linked to the FHAB construct, for which it is pursuing clinical development in solid tumors. Its lead clinical-stage asset, SON-080, is a fully human version of IL-6 manufactured in Chinese hamster ovary (CHO) cells. SON-080 is in various clinical stages for indications, such as chemotherapy-induced peripheral neuropathy (CIPN) and diabetic peripheral neuropathy (DPN). Its pipeline also includes SON-1210, SON-1410 and SON-1410.

Webull offers kinds of Sonnet Biotherapeutics Holdings Inc stock information, including NASDAQ:SONN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SONN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SONN stock methods without spending real money on the virtual paper trading platform.